Company profile for Ra Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Our goal is to become a leading biopharmaceutical company transforming the lives of patients with life-threatening complement-mediated diseases by combining our insights into complement with our leadership in macrocycle chemistry technology. Ra Pharma® has leveraged the Extreme Diversity™ platform to rapidly develop a portfolio of products that selectively inhibit the complement system and other immune targets, including...
Our goal is to become a leading biopharmaceutical company transforming the lives of patients with life-threatening complement-mediated diseases by combining our insights into complement with our leadership in macrocycle chemistry technology. Ra Pharma® has leveraged the Extreme Diversity™ platform to rapidly develop a portfolio of products that selectively inhibit the complement system and other immune targets, including its lead program zilucoplan (RA101495 SC). Ra Pharma’s transformational technology can provide products to replace injectable biologics for a range of common and rare diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
87 Cambridge Park Drive Cambridge, MA 02140
Telephone
Telephone
(617) 401-4060
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-09-09/vyome-holdings-strengthens-leadership-team-with-industry-veterans-as-it-plans-pivotal-trial-studies

PHARMAWEB
09 Sep 2025

https://www.fiercebiotech.com/biotech/ucb-races-to-regulators-after-2-5b-rare-disease-bet-delivers-data-for-attack-astrazeneca

N.P. Taylor FIERCEBIOTECH
05 Feb 2022

https://www.biopharmadive.com/news/lightstone-venture-capital-fund-raise-biotech/606545/

BIOPHARMADIVE
14 Sep 2021
Another OTC product sale for Sanofi, this one to Hypera Pharma
Another OTC product sale for Sanofi, this one to Hypera Pharma

14 Jul 2021

// Kevin Dunleavy FIERCEPHARMA

https://www.fiercepharma.com/pharma/deal-hypera-brazil-sanofi-continues-to-tighten-belt-and-transform-consumer-healthcare-unit

Kevin Dunleavy FIERCEPHARMA
14 Jul 2021

https://www.biospace.com/article/releases/ucb-completes-the-acquisition-of-ra-pharmaceuticals-to-deliver-differentiated-therapies-to-patients/?s=79

BIOSPACE
02 Apr 2020

https://www.businesswire.com/news/home/20200218005177/en

BUSINESSWIRE
18 Feb 2020

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty